Epigenomics is the study of the complete set of chemical modifications to DNA and its associated proteins that control which genes are active in a cell. These marks, such as the attachment of methyl groups to DNA, do not alter the genetic sequence itself. They explain how cells with identical DNA become different tissues. The field is a branch of genomics and relies on the same sequencing technology.
Its commercial uses are mainly in medicine. Tests that read methylation patterns in blood are being developed to detect cancers early. Because epigenetic marks are reversible, they are also a target for new therapies, some of which borrow tools from gene editing. In thematic investing, epigenomics is grouped with other genomic technologies. Companies in the area are often early-stage and funded by venture capital, and their value depends on trial results, regulatory approval and whether insurers pay for the tests.